We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+35.87%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$211M
AUM Growth
-$31.9M
(-13%)
Cap. Flow
-$83.2M
Cap. Flow
% of AUM
-39.42%
Top 10 Holdings %
Top 10 Hldgs %
8.5%
Holding
499
New
89
Increased
112
Reduced
218
Closed
57
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Delek Logistics
DKL
|
+$1.29M |
| 2 |
Western Midstream Partners
WES
|
+$970K |
| 3 |
Viper Energy
VNOM
|
+$883K |
| 4 |
Canadian Natural Resources
CNQ
|
+$761K |
| 5 |
EPR Properties
EPR
|
+$729K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Barings BDC
BBDC
|
+$2.49M |
| 2 |
Prospect Capital
PSEC
|
+$2.37M |
| 3 |
BKCC
BlackRock Capital Investment Corporation
BKCC
|
+$2.34M |
| 4 |
Nuveen Credit Strategies Income Fund
JQC
|
+$2.3M |
| 5 |
WhiteHorse Finance
WHF
|
+$2.12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.94% |
| 2 | Real Estate | 15.9% |
| 3 | Energy | 15.5% |
| 4 | Materials | 8.79% |
| 5 | Financials | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Akebia Therapeutics
AKBA
$343M
| $425K | 0.2% |
31,293
-24,977
| -44% | -$258K |
|
177
Corbus Pharmaceuticals
CRBP
$171M
| $425K | 0.2% |
1,690
-688
| -29% | -$139K |
|
178
Main Street Capital
MAIN
$5.01B
| $423K | 0.2% |
13,585
-37,653
| -73% | -$1.06M |
|
179
AnaptysBio
ANAB
$1.62B
| $422K | 0.2% |
18,899
-3,956
| -17% | -$72.3K |
|
|
SYRS
180
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $422K | 0.2% |
+3,958
| New | +$355K |
|
181
Sixth Street Specialty
TSLX
$1.63B
| $421K | 0.2% |
25,549
-91,001
| -78% | -$1.51M |
|
|
KRTX
182
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $420K | 0.2% |
3,766
-1,750
| -32% | -$152K |
|
183
Vir Biotechnology
VIR
$1.51B
| $419K | 0.2% |
+10,226
| New | +$343K |
|
|
TBIO
184
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $419K | 0.2% |
23,395
-18,217
| -44% | -$275K |
|
185
Arcutis Biotherapeutics
ARQT
$3.52B
| $415K | 0.2% |
+13,718
| New | +$396K |
|
186
Kiniksa Pharmaceuticals
KNSA
$4.98B
| $415K | 0.2% |
+16,274
| New | +$340K |
|
|
LITS
187
Lite Strategy Inc
LITS
$33.1M
| $414K | 0.2% |
+5,018
| New | +$304K |
|
|
MRSN
188
DELISTED
Mersana Therapeutics
MRSN
| $411K | 0.19% |
+703
| New | +$240K |
|
189
Korro Bio
KRRO
$152M
| $409K | 0.19% |
+352
| New | +$318K |
|
190
Bain Capital Specialty
BCSF
$815M
| $408K | 0.19% |
36,795
-24,553
| -40% | -$254K |
|
|
IGMS
191
DELISTED
IGM Biosciences
IGMS
| $408K | 0.19% |
+5,592
| New | +$340K |
|
192
CEL-SCI Corp
CVM
$20.8M
| $405K | 0.19% |
904
-644
| -42% | -$264K |
|
193
Rocket Pharmaceuticals
RCKT
$360M
| $404K | 0.19% |
19,310
+2,895
| +18% | +$52.2K |
|
194
Xencor
XNCR
$1.48B
| $399K | 0.19% |
12,325
+2,692
| +28% | +$82.5K |
|
195
Axsome Therapeutics
AXSM
$12.3B
| $398K | 0.19% |
4,839
-2,849
| -37% | -$219K |
|
196
BridgeBio Pharma
BBIO
$16.6B
| $398K | 0.19% |
12,211
+2,351
| +24% | +$71.6K |
|
|
PHD
197
DELISTED
Pioneer Floating Rate Fund
PHD
| $398K | 0.19% |
41,811
-170,439
| -80% | -$1.5M |
|
|
TVRD
198
Tvardi Therapeutics
TVRD
$23.7M
| $398K | 0.19% |
647
+44
| +7% | +$24.3K |
|
199
TG Therapeutics
TGTX
$8.56B
| $397K | 0.19% |
20,382
-15,224
| -43% | -$245K |
|
|
AGEN
200
Agenus
AGEN
$257M
| $394K | 0.19% |
5,113
+343
| +7% | +$20.5K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2020 Portfolio in Review
As of Q2 2020, Virtus ETF Advisers held 499 positions worth $211M, down 13% from $243M the previous quarter. Its ten largest holdings account for 8.5% of the portfolio.
Virtus ETF Advisers withdrew a net $83.2M in Q2 2020, closing 57 positions and reducing 218 holdings. Its most notable exit was Tallgrass Energy, LP Class A Shares, an estimated $1.22M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 34% of assets, up from 20% a quarter earlier, followed by Real Estate and Energy.
Against the trend, Virtus ETF Advisers opened a new position in Verastem worth $342K.
- Virtus ETF Advisers's largest Q2 2020 buy was Verastem: 16,584 shares worth $342K.
- Virtus ETF Advisers added most to Delek Logistics in Q2 2020, an estimated $1.29M increase.
- Virtus ETF Advisers's biggest Q2 2020 reduction was Barings BDC, cutting an estimated $2.49M.
- Virtus ETF Advisers fully exited Tallgrass Energy, LP Class A Shares in Q2 2020, selling an estimated $1.22M.
- Virtus ETF Advisers's ten largest holdings make up 8.5% of its $211M portfolio in Q2 2020.
- Virtus ETF Advisers opened 89 new positions and closed 57 in Q2 2020.
- Virtus ETF Advisers's portfolio value fell 13% quarter-over-quarter to $211M.
Based on Virtus ETF Advisers's 13F filing for Q2 2020, filed 5 Aug 2020.